ClinicalTrials.gg
CompletedNCT03875092Updated Oct 1, 2024Results posted

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

A Phase 3 interventional study of Pembrolizumab and Paclitaxel in Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Apr 2017, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung — 29 open to participants now, 48 under way, 13 of them phase 3. pembrolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
46th of 127
125 · median 65
Started
2017
with 14 others
Phase 3
28 of 127
4 open now
Registered
61st of 127
by date
Lead sponsor
27 of 127
Merck Sharp & Dohme LLC

Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 46th largest by enrollment, is one of 15 that started in 2017, is one of 28 in phase 3, and was the 61st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

29 of the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 10 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

In this China extension study, carboplatin and paclitaxel with or without pembrolizumab (MK-3475, KEYTRUDA®) will be administered to Chinese adults with first line metastatic squamous non-small cell lung cancer (NSCLC).

The primary hypotheses are that treatment with pembrolizumab prolongs: 1) Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by a blinded central imaging vendor compared to placebo, and 2) Overall Survival (OS) in Chinese participants.

After analysis of interim results was conducted, the protocol was amended (Amendment 5) to allow participants the option to discontinue placebo in the control arm and to switch to pembrolizumab in the event of documented progressive disease as assessed by central review.

Read the detailed description

The MK-3475-407-China Extension Study enrolled a total of 125 participants, of which 15 participants have been also previously enrolled in the MK-3475-407 global study (NCT02775435). This China extension study did not include nano particle albumin-bound paclitaxel (nab-paclitaxel) that was an option in the global base study, because nab-paclitaxel it is not yet approved for treatment of NSCLC in China.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a or cytologically confirmed diagnosis of stage IV (M1a or M1b-American Joint Committee on Cancer [AJCC]) squamous NSCLC.
  • Has based on 1.1 as determined by the local site investigator/radiology assessment.
  • Has not received prior systemic treatment for NSCLC.
  • Has provided tumor tissue from locations not radiated prior to .
  • Has a of at least 3 months.
  • Has a performance status of 0 or 1 on the (ECOG) Performance Status.
  • Has adequate organ function.
  • If female of , is willing to use an adequate method of for the course of the study through 180 days after the last dose of study treatment.
  • If male with a female partner(s) of child-bearing potential, must agree to use an adequate method of contraception starting with the first dose of study treatment through 95 days after the last dose of study treatment. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

Exclusion criteria

Exclusion Criteria:

  • Has non-squamous histology NSCLC.
  • Is currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.
  • Before the first dose of study drug: a) Has received prior systemic cytotoxic chemotherapy for disease; b) Has received other targeted or biological antineoplastic therapy (e.g., erlotinib, crizotinib, cetuximab) for metastatic disease; c) Has had major surgery (\<3 weeks prior to first dose).
  • Received radiation therapy to the lung that is >30 Gray (Gy) within 6 months of the first dose of study treatment.
  • Completed palliative radiotherapy within 7 days of the first dose of study treatment.
  • Is expected to require any other form of antineoplastic therapy while on study.
  • Has received a live-virus vaccination within 30 days of planned treatment start.
  • Has a known history of prior except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Has pre-existing peripheral neuropathy that is ≥ Grade 2 by (CTCAE) Version 4 criteria.
  • Previously had a severe reaction to treatment with another monoclonal antibody.
  • Has a known sensitivity to any component of carboplatin or paclitaxel or nab-paclitaxel.
  • Has active disease that has required systemic treatment in past 2 years.
  • Is on chronic systemic .
  • Had prior treatment with any other anti-programmed cell death 1 (), or programmed cell death ligand 1 (PD-L1) or PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors or mechanisms.
  • Has participated in any other pembrolizumab trial and has been treated with pembrolizumab.
  • Has an active infection requiring therapy.
  • Has known history of (HIV).
  • Has known active virus (HBV) or virus (HCV) infection.
  • Is, at the time of providing documented , a regular user (including "recreational use") of any illicit drugs or has a recent history (within the last year) of substance abuse (including alcohol).
  • Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Chemotherapy

    Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.

    Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Carboplatin

  • Active comparator
    Chemotherapy

    Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS paclitaxel (200 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.

    Drug: Paclitaxel · Drug: Carboplatin · Drug: Saline placebo for pembrolizumab

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: MK-3475, KEYTRUDA®

  • IV infusion

    Also known as: TAXOL®

  • IV infusion Carboplatin dose should not exceed 900 mg.

    Also known as: PARAPLATIN®

  • DrugSaline placebo for pembrolizumab

    IV infusion

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of ≥1 new lesions was also considered PD. PFS as assessed by blinded independent central review per RECIST 1.1 is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 33 months

  2. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. OS is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 39 months

Secondary outcomes

  1. Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by RECIST 1.1. ORR as assessed by blinded independent central review per RECIST 1.1 is presented.

    Time frame: Up to approximately 33 months

  2. Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    For participants who demonstrated a confirmed response (Complete Response \[CR\]: Disappearance of all target lesions or Partial Response \[PR\]: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression as assessed by RECIST 1.1 or death. DOR as assessed by blinded independent central review per RECIST 1.1 is presented.

    Time frame: Up to approximately 30 months

  3. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 31 months

  4. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

    The number of participants who discontinued study treatment due to an AE is presented.

    Time frame: Up to approximately 29 months

07

Results

Posted Oct 20, 2021

Participant flow

The China extension study included participants previously enrolled in China in the global study for MK-3475-407 (NCT02775435) plus those enrolled during the China extension enrollment period.

Participant flow — Overall Study
MilestonePembrolizumab + ChemotherapyChemotherapy
Started6560
Treated6560
Switched to pembrolizumab+chemotherapy038
Received second course of pembrolizumab60
Completed00
Not completed6560
Withdrew: Adverse event25
Withdrew: Death4451
Withdrew: Participation was terminated by sponsor194

Outcome measures

PrimaryProgression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of ≥1 new lesions was also considered PD. PFS as assessed by blinded independent central review per RECIST 1.1 is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 33 months
Reported as:
Median · Months
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPembrolizumab + ChemotherapyChemotherapy
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)8.3 (6.2 to 10.5)4.2 (4.0 to 5.4)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Chemotherapy · Hazard ratio (hr): 0.35 · 95% CI 0.24 to 0.52Based on unstratified Cox regression model with treatment as a covariate, due to small sample size.
PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. OS is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 39 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + ChemotherapyChemotherapy
Overall Survival (OS)30.1 (18.2 to NA)12.7 (9.4 to 17.3)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Chemotherapy · Hazard ratio (hr): 0.44 · 95% CI 0.28 to 0.70Based on unstratified Cox regression model with treatment as a covariate, due to small sample size.
SecondaryObjective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by RECIST 1.1. ORR as assessed by blinded independent central review per RECIST 1.1 is presented.

Time frame:
Up to approximately 33 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Percentage of ParticipantsPembrolizumab + ChemotherapyChemotherapy
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)80.0 (68.2 to 88.9)43.3 (30.6 to 56.8)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Chemotherapy · Difference in percentage: 36.7 · 95% CI 19.9 to 51.6Based on unstratified Miettinen \& Nurminen method, due to small sample size.
SecondaryDuration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

For participants who demonstrated a confirmed response (Complete Response \[CR\]: Disappearance of all target lesions or Partial Response \[PR\]: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression as assessed by RECIST 1.1 or death. DOR as assessed by blinded independent central review per RECIST 1.1 is presented.

Time frame:
Up to approximately 30 months
Reported as:
Median · Months
Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPembrolizumab + ChemotherapyChemotherapy
Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)7.1 (4.9 to 14.4)3.5 (2.8 to 4.9)
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE is presented. Data are from the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to approximately 31 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumab + ChemotherapyChemotherapy
Number of Participants Who Experienced an Adverse Event (AE)6560
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

The number of participants who discontinued study treatment due to an AE is presented.

Time frame:
Up to approximately 29 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
ParticipantsPembrolizumab + ChemotherapyChemotherapy
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)84

Adverse events

Collected over All-Cause mortality: Up to 1948 days Adverse events: Up to 1625 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Chemotherapy41/65 (63.1%)35/65 (53.8%)65/65 (100%)
Chemotherapy22/60 (36.7%)22/60 (36.7%)60/60 (100%)
Chemotherapy > Pembrolizumab Switch Over34/38 (89.5%)10/38 (26.3%)32/38 (84.2%)
Pembrolizumab > Pembrolizumab Second Course5/6 (83.3%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventPembrolizumab + ChemotherapyChemotherapyChemotherapy > Pembrolizumab Switch OverPembrolizumab > Pembrolizumab Second Course
PneumoniaInfections and infestations6/655/605/380/6
NeutropeniaBlood and lymphatic system disorders5/651/600/380/6
ThrombocytopeniaBlood and lymphatic system disorders4/652/600/380/6
Febrile neutropeniaBlood and lymphatic system disorders3/653/600/380/6
LeukopeniaBlood and lymphatic system disorders3/650/600/380/6
PyrexiaGeneral disorders0/652/601/380/6
HaemoptysisRespiratory, thoracic and mediastinal disorders0/652/600/380/6
Upper respiratory tract infectionInfections and infestations2/650/600/380/6
Neutrophil count decreasedInvestigations2/650/600/380/6
Diabetic ketoacidosisMetabolism and nutrition disorders2/650/600/380/6
Most frequent other events
Showing 10 of 78
Most frequent other events
EventPembrolizumab + ChemotherapyChemotherapyChemotherapy > Pembrolizumab Switch OverPembrolizumab > Pembrolizumab Second Course
White blood cell count decreasedInvestigations51/6542/600/381/6
AlopeciaSkin and subcutaneous tissue disorders51/6540/600/380/6
Neutrophil count decreasedInvestigations50/6543/600/381/6
AnaemiaBlood and lymphatic system disorders42/6546/6011/381/6
HypoaesthesiaNervous system disorders29/6522/600/380/6
Decreased appetiteMetabolism and nutrition disorders25/6519/605/380/6
NauseaGastrointestinal disorders24/6513/602/380/6
Alanine aminotransferase increasedInvestigations24/6517/606/381/6
Platelet count decreasedInvestigations16/6522/601/381/6
ArthralgiaMusculoskeletal and connective tissue disorders23/6514/602/380/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + ChemotherapyChemotherapyTotal
Mean61.6 ± 8.761.5 ± 9.161.5 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + ChemotherapyChemotherapyTotal
Female336
Male6257119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + ChemotherapyChemotherapyTotal
Hispanic or Latino000
Not Hispanic or Latino6560125
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + ChemotherapyChemotherapyTotal
American Indian or Alaska Native000
Asian6560125
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Level: Tumor Proportion Score (TPS)
Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Level: Tumor Proportion Score (TPS)(Participants)Pembrolizumab + ChemotherapyChemotherapyTotal
TPS <1%252348
TPS ≥1%373572
Unknown325
Taxane Chemotherapy
Taxane Chemotherapy(Participants)Pembrolizumab + ChemotherapyChemotherapyTotal
+Paclitaxel6560125
+Nab-paclitaxel000
Geographic Region
Geographic Region(Participants)Pembrolizumab + ChemotherapyChemotherapyTotal
East Asia6560125
Non-East Asia000
08

Study locations

1 site
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
09

References and documents

Publications

  • Cheng Y, Zhang L, Hu J, Wang D, Hu C, Zhou J, Wu L, Cao L, Liu J, Zhang H, Sun H, Wang Z, Gao H, Sun Y, Li B, Hu X, Schwarzenberger P, Paz-Ares L. Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407. JTO Clin Res Rep. 2021 Sep 25;2(10):100225. doi: 10.1016/j.jtocrr.2021.100225. eCollection 2021 Oct. PubMed 34661177 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Sep 2020, 41 months.

Results were first posted in Oct 2021, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 41 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2019
First posted
Mar 14, 2019
StartActual
Apr 21, 2017
Primary completionActual
Sep 30, 2020
CompletionActual
Sep 14, 2023
Results first posted
Oct 20, 2021
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03875092
Responsible party
Sponsor
First posted
Mar 14, 2019
Start date
Apr 21, 2017
Primary completion
Sep 30, 2020
Completion
Sep 14, 2023
Results posted
Oct 20, 2021
Last update
Oct 1, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion